{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.52","value":"-25.3"},{"groupId":"OG001","spread":"61.26","value":"-36.9"},{"groupId":"OG002","spread":"46.99","value":"-35.4"}]}],"title":"Week 24 [N=172, 166, 170]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.95","value":"-39.4"},{"groupId":"OG001","spread":"74.54","value":"-40.5"},{"groupId":"OG002","spread":"40.01","value":"-49.0"}]}],"title":"Week 48 [N=172, 166, 170]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"167"},{"groupId":"OG002","value":"170"}],"units":"Participants"}],"description":"The physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS, where the left-hand extreme of the line (0 mm) was described as \"no disease activity\" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as \"maximum disease activity\".\n\nThe percentage change from baseline at each post-baseline visit was calculated as:\n\n\\[(post-baseline value minus baseline value) divided by Baseline value\\]\\*100.\n\nA negative percentage change from baseline score indicates an improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study.\n\nAll participants entered a 48-week safety follow-up (SFU) period following the treatment period.","id":"OG000","title":"Placebo + MTX"},{"description":"Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.\n\nParticipants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.\n\nAll participants entered a 48-week safety follow-up (SFU) period following the treatment period.","id":"OG001","title":"Rituximab 2 x 0.5 g + MTX"},{"description":"Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.\n\nParticipants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.\n\nAll participants entered a 48-week safety follow-up (SFU) period following the treatment period.","id":"OG002","title":"Rituximab 2 x 1.0 g + MTX"}],"paramType":"MEAN","populationDescription":"Intent-to-treat population, LOCF was used. \"N\" indicates the number of participants with non-missing data at each time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 24 and Week 48","title":"Percent Change From Baseline in Physician's Global Assessment of Disease Activity","type":"SECONDARY","unitOfMeasure":"percent change"}